The application of plate-shaped ablation hemostatic electrode in surgery

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400090978

Enrollment

Unknown

Registered

2024-10-17

Start date

2024-03-15

Completion date

Unknown

Last updated

2024-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver tumor

Interventions

plate-shaped ablation hemostatic electrode group:Sectional hemostasis tools necessary for transecting liver parenchyma selected for use with plasma needle discharge hemostatic electrode of this projec

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: a. Patients requiring partial hepatectomy for various reasons b. General condition can be tolerated: specifically including: general condition is good, no obvious heart, lung, kidney and other important organs organic lesions c. The reserved liver can be compensated: liver function Child-Pugh A, or A after short-term treatment; liver reserve function (such as ICG.R15) is basically normal;

Exclusion criteria

Exclusion criteria: a. Liver tumor with distant metastasis, or diffuse liver cancer b. Liver disease combined with severe cirrhosis, liver function damage is more serious c. There are obvious jaundice, ascites, edema, cachexia, etc. d. accompanied by serious heart, lung and kidney diseases, unable to accept surgical treatment e. accompanied by severe bleeding tendency f. Obvious portal hypertension with gastric fundus esophageal varices

Design outcomes

Primary

Measure	Time frame
the amount of intraoperative bleeding;	—

Secondary

Measure	Time frame
operation time;postoperative complications;	—

Countries

China

Contacts

Public ContactFeng Xi

West China Hospital of Sichuan University

fengxi@wchscu.cn+86 189 8060 2509

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026